<?xml version='1.0' encoding='utf-8'?>
<document id="15493948"><sentence text="Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics." /><sentence text="The incidence of cancer is highest among individuals &gt; or =65 years of age" /><sentence text=" Physiological changes associated with aging, such as cognitive decline, renal and hepatic dysfunction, can often complicate treatment options, and the elderly represent a particular challenge to the oncologist because of the high incidence of comorbidity and polypharmacy" /><sentence text=" Effective supportive care is of particular importance in elderly cancer patients as they may recover less satisfactorily if adverse events are poorly controlled" /><sentence text=" Nevertheless, evidence suggests that supportive care agents, for example, antiemetics, are underutilised in this patient population" /><sentence text=" Chemotherapy and radiotherapy regimens are frequently associated with nausea and vomiting--symptoms that can have deleterious effects on vulnerable patients if not adequately managed" /><sentence text=" The serotonin 5-HT3-receptor antagonists represent a class of antiemetics that are currently regarded as the gold standard treatment for chemotherapy- and radiotherapy-induced nausea and vomiting"><entity charOffset="5-14" id="DDI-PubMed.15493948.s7.e0" text="serotonin" /><entity charOffset="110-114" id="DDI-PubMed.15493948.s7.e1" text="gold" /><pair ddi="false" e1="DDI-PubMed.15493948.s7.e0" e2="DDI-PubMed.15493948.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15493948.s7.e0" e2="DDI-PubMed.15493948.s7.e1" /></sentence><sentence text=" They are recommended as first-line treatment for patients at moderate-to-high risk of emesis" /><sentence text=" However, antiemetic guidelines do not differentiate between these agents and, more importantly, do not contain specific recommendations for the elderly" /><sentence text=" Pharmacological differences exist between the commonly available 5-HT3-receptor antagonists (dolasetron, granisetron, ondansetron, tropisetron and palonosetron), namely receptor sensitivity, duration of action, metabolism and tolerability profile"><entity charOffset="94-104" id="DDI-PubMed.15493948.s10.e0" text="dolasetron" /><entity charOffset="106-117" id="DDI-PubMed.15493948.s10.e1" text="granisetron" /><entity charOffset="119-130" id="DDI-PubMed.15493948.s10.e2" text="ondansetron" /><entity charOffset="132-143" id="DDI-PubMed.15493948.s10.e3" text="tropisetron" /><entity charOffset="148-160" id="DDI-PubMed.15493948.s10.e4" text="palonosetron" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e0" e2="DDI-PubMed.15493948.s10.e0" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e0" e2="DDI-PubMed.15493948.s10.e1" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e0" e2="DDI-PubMed.15493948.s10.e2" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e0" e2="DDI-PubMed.15493948.s10.e3" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e0" e2="DDI-PubMed.15493948.s10.e4" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e1" e2="DDI-PubMed.15493948.s10.e1" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e1" e2="DDI-PubMed.15493948.s10.e2" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e1" e2="DDI-PubMed.15493948.s10.e3" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e1" e2="DDI-PubMed.15493948.s10.e4" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e2" e2="DDI-PubMed.15493948.s10.e2" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e2" e2="DDI-PubMed.15493948.s10.e3" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e2" e2="DDI-PubMed.15493948.s10.e4" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e3" e2="DDI-PubMed.15493948.s10.e3" /><pair ddi="false" e1="DDI-PubMed.15493948.s10.e3" e2="DDI-PubMed.15493948.s10.e4" /></sentence><sentence text=" Of particular concern with prescriptions to elderly cancer patients is the convenience of once-daily administration, the low potential for drug-drug interactions and cardiovascular adverse effect profile" /><sentence text=" Moreover, the addition of the newly approved neurokinin NK1-receptor antagonist aprepitant to the choice of antiemetic regimen may complicate therapy and exacerbate the drug-drug interaction risk in elderly patients" /><sentence text=" Therefore, the use of antiemetics that are well tolerated and with the lowest risk of drug-drug interactions is imperative in this patient population and will enable even those patients with several comorbidities and a high level of polypharmacy to receive effective antiemetic therapy" /><sentence text="" /></document>